Elekta (EKTABS) Stock Overview
A medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
EKTABS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Elekta AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 53.80 |
| 52 Week High | SEK 60.88 |
| 52 Week Low | SEK 42.24 |
| Beta | 1.06 |
| 1 Month Change | 6.17% |
| 3 Month Change | 15.77% |
| 1 Year Change | n/a |
| 3 Year Change | -12.78% |
| 5 Year Change | -51.53% |
| Change since IPO | -84.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| EKTABS | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 16.6% | 1.3% | 2.0% |
| 1Y | n/a | 14.3% | 16.1% |
Return vs Industry: Insufficient data to determine how EKTABS performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how EKTABS performed against the UK Market.
Price Volatility
| EKTABS volatility | |
|---|---|
| EKTABS Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: EKTABS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine EKTABS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | 4,485 | Jakob Just-Bomholt | www.elekta.com |
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers linear accelerator and radiation therapy products comprising Elekta Unity for anatomy-specific MR imaging; Elekta Evo that delivers offline and online adaptive radiation therapy; Elekta Versa HD, a brain metastases solution; Elekta Harmony; and Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs, as well as quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit, a gamma knife system; and Leksell GammaPlan, a treatment planning and management software, as well as Elekta ONE, an oncology software suite.
Elekta AB (publ) Fundamentals Summary
| EKTABS fundamental statistics | |
|---|---|
| Market cap | SEK 21.01b |
| Earnings (TTM) | SEK 274.00m |
| Revenue (TTM) | SEK 17.84b |
Is EKTABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EKTABS income statement (TTM) | |
|---|---|
| Revenue | SEK 17.84b |
| Cost of Revenue | SEK 11.12b |
| Gross Profit | SEK 6.71b |
| Other Expenses | SEK 6.44b |
| Earnings | SEK 274.00m |
Last Reported Earnings
Jul 31, 2025
Next Earnings Date
Mar 05, 2026
| Earnings per share (EPS) | 0.72 |
| Gross Margin | 37.64% |
| Net Profit Margin | 1.54% |
| Debt/Equity Ratio | 72.0% |
How did EKTABS perform over the long term?
See historical performance and comparisonDividends
Does EKTABS pay a reliable dividends?
See EKTABS dividend history and benchmarks| Elekta dividend dates | |
|---|---|
| Ex Dividend Date | Mar 05 2026 |
| Dividend Pay Date | Mar 11 2026 |
| Days until Ex dividend | 97 days |
| Days until Dividend pay date | 103 days |
Does EKTABS pay a reliable dividends?
See EKTABS dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/26 20:03 |
| End of Day Share Price | 2025/11/26 00:00 |
| Earnings | 2025/07/31 |
| Annual Earnings | 2025/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Elekta AB (publ) is covered by 30 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Alexander Kleban | Barclays |
| Sally Taylor | Barclays |